Critical Path for Parkinson's Consortium: Advancing Drug Development Tools and Regulatory Science for PD therapeutic trials

被引：0

作者：

Romero, K. ^{[1
]}

Akalu, M. ^{[1
]}

Alexander, R. ^{[2
]}

Bloem, B. R. ^{[4
]}

Boroojerdi, B. ^{[3
]}

Burn, D. ^{[5
]}

Cedarbaum, J. ^{[6
]}

Conrado, D. ^{[1
]}

Dexter, D. T. ^{[7
]}

Dorsey, E. R. ^{[8
,12
]}

Facheris, M. ^{[9
]}

Fischer, T. ^{[10
]}

Frasier, M. ^{[11
]}

Gallagher, J. ^{[7
]}

Gordon, M. Forrest ^{[12
]}

Grosset, D. ^{[13
]}

Hill, D. ^{[12
]}

Ho, C. ^{[14
]}

Hu, M. T. ^{[15
]}

Kieburtz, K. ^{[8
,12
]}

Lassen, A. B. ^{[16
]}

Lawson, R. ^{[5
]}

Macha, S. ^{[17
]}

Marek, K. ^{[18
]}

Taylor, K. ^{[19
]}

Russell, D. ^{[18
]}

Seibyl, J. ^{[18
]}

Stafford, B. ^{[1
]}

Stebbins, G. ^{[20
]}

Venuto, C. ^{[8
,12
]}

Williams-Gray, C. ^{[21
]}

Yarnall, A. ^{[5
]}

Stephenson, D. ^{[1
]}

机构：

[1] Crit Path Inst, Tucson, AZ USA

[2] Takeda, Tokyo, Japan

[3] UCB Pharma, Brussels, Belgium

[4] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[5] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England

[6] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA

[7] Parkinsons UK, London, England

[8] Univ Rochester, Rochester, NY 14627 USA

[9] AbbVie Inc, N Chicago, IL USA

[10] Sanofi, Paris, France

[11] Michael J Fox Fdn, New York, NY USA

[12] Advisor CPP, Toronto, ON, Canada

[13] Univ Glasgow, Glasgow, Lanark, Scotland

[14] Denali Therapeut, San Francisco, CA USA

[15] Univ Oxford, Oxford, England

[16] Lundbeck, Copenhagen, Denmark

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Inst Neurodegenerat Disorders, New Haven, CT USA

[19] Roche, Basel, Switzerland

[20] Rush Univ, Advisor CPP, Chicago, IL 60612 USA

[21] Univ Cambridge, Cambridge, England

来源：

MOVEMENT DISORDERS | 2019年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S17 / S17

页数：1

共 46 条

[21] Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance of Anti Parkinson's Therapy
Verma, N.
MOVEMENT DISORDERS, 2018, 33 : S634 - S635
[22] Accelerating Pediatric Drug Development: A 2022 Special Issue of Therapeutic Innovation & Regulatory Science
McCune, Susan
Portman, Ronald J.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2022, 56 (06) : 869 - 872
[23] Accelerating Pediatric Drug Development: A 2022 Special Issue of Therapeutic Innovation & Regulatory Science
Susan McCune
Ronald J. Portman
Therapeutic Innovation & Regulatory Science, 2022, 56 : 869 - 872
[24] Current Approaches and Tools Used in Drug Development against Parkinson's Disease
Koszla, Oliwia
Stepnicki, Piotr
Zieba, Agata
Grudzinska, Angelika
Matosiuk, Dariusz
Kaczor, Agnieszka A.
BIOMOLECULES, 2021, 11 (06)
[25] Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable
Eberling, Jamie
Vincent, Lona
Goldman, Jennifer G.
Weintraub, Daniel
Kulisevsky, Jaime
Marras, Connie
Stebbins, Glenn
Kieburtz, Karl
JOURNAL OF PARKINSONS DISEASE, 2014, 4 (04) : 585 - 589
[26] Catalyzing the Critical Path Initiative: FDA's Progress in Drug Development Activities
Parekh, A.
Buckman-Garner, S.
McCune, S.
ONeill, R.
Geanacopoulos, M.
Amur, S.
Clingman, C.
Barratt, R.
Rocca, M.
Hills, I.
Woodcock, J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (03) : 221 - 233
[27] Digital Health Technology to Measure Drug Efficacy in Clinical Trials for Parkinson's Disease: A Regulatory Perspective
Sacks, Leonard
Kunkoski, Elizabeth
JOURNAL OF PARKINSONS DISEASE, 2021, 11 : S111 - S115
[28] How the Critical Path Initiative Addresses CDER's Regulatory Science Needs: Some Illustrative Examples
Geanacopoulos, Mark
Barratt, Ruth
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (04) : 466 - 472
[29] How the Critical Path Initiative Addresses CDER’s Regulatory Science Needs: Some Illustrative Examples
Mark Geanacopoulos
Ruth Barratt
Therapeutic Innovation & Regulatory Science, 2015, 49 : 466 - 472
[30] Optimizing Patient-Centric Clinical Outcome Assessments for Use in Parkinson's Disease Clinical Trials: Critical Path for Parkinson's Multistakeholder Initiative
Speck, R.
Trundell, D.
Cedarbaum, J. M.
Campbell, M.
Chin, P. S.
Crawford, S.
Dam, T.
Dexter, D. T.
Goldfine, A. M.
Klapper, K.
Kopil, C. M.
Lee, S. J.
Marek, K.
Matthews, H.
Mestre, T.
Morel, T.
Minchik, M.
Muller, M. L. T. M.
Schroeder, K.
Simuni, T.
Stebbins, G. T.
Yan, C. H.
Zeissler, M. L.
Stephenson, D.
MOVEMENT DISORDERS, 2022, 37 : S32 - S33

← 1 2 3 4 5 →